India, June 12 -- Medicus Pharma Ltd. (MDCX) announced that it submitted an Investigational New Drug (IND) application to the Department of Health, Abu Dhabi, for a Phase 2a PRECISION-E2 genomics-enabled trial to evaluate Teverelix in women with symptomatic endometriosis in the United Arab Emirates (UAE).
Company Profile
Medicus Pharma is a clinical-stage biotechnology company focused on advancing novel therapeutic and drug-delivery technologies. Its pipeline includes SkinJect, a microneedle-based therapy for basal cell carcinoma, and it has a strategic collaboration with the Gorlin Syndrome Alliance to provide access to patients with Gorlin Syndrome.
Endometriosis
Endometriosis is a chronic estrogen-dependent inflammatory disease assoc...